HUTCHMED Makes Major Move in Non-Toxin ADC Space with HMPL-A251 IPO Filing

Jan 07, 2026 08:58 CST Updated 08:58

HUTCHMED

Biopharmaceutical Manufacturer

Jacobio

Innovative Drug Developer

Hengrui Pharma

Innovative and High-Quality Pharmaceutical Developer

Simcere

Innovative Drug Developer

Huaota

Biological New Drug Developer

CHIATAI TIANQING

High-quality pharmaceuticals research, production, and sales provider

Note:This article does not constitute any investment opinions or recommendations; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprints require authorization.

PharmaCircleSupervisorMeasurement DisplayIndication：HUTCHMED Makes a Strong Move into Alternative ADCs.

The first product is as follows

Clinical Development Plan

HMPL-A251 is a first-in-class PI3K/PIKK-HER2 antibody-targeted conjugate drug, composed of a PI3K/PIKK inhibitor conjugated with an anti-HER2 antibody. The study will be conducted in the United States and China, with the first patient receiving the initial dosing treatment in China on December 16, 2025. The trial aims to evaluate the safety and tolerability of HMPL-A251 as a monotherapy for patients with HER2-expressing solid tumors.Among them, the HER2 antibody is a biosimilar.

Leave a business card in the background to receive the above PDF.

PharmaCircle monitoring shows: In China, there are still many companies laying out non-toxin ADCs, such as Chipscreen Biosciences, Jacobio, Arno, GenFleet, Hengrui Pharma, Simcere, Lead Therapeutics, Tianrun, DualityBio, Huaota, Kanghong, CHIATAI TIANQING, etc.

References:

PharmCube Data;

Moxie Pharma pharma.bcpmdata.com (formerly known as Yaoke Cloud Data);

http://net.bangong.cn:61151/about/index.html；

https://www.hutch-med.com/wp-content/uploads/2025/11/pre251106_sc.pdf；

; etc.

Copyright Statement: This article is reproduced from PharmaCircle info, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.